drug
evolocumab
Marketedupdated 6mo agoby $AMGN AMGEN INC
Approvedannual revenue · 2024–2024peak $2.4B
community read0 votes
indications
investigational
Hyperlipidemia
all catalysts(0)
nothing on the calendar yet
Trials studying evolocumab
- phase4EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
- phase2YN001-004 in Patients With Coronary Atherosclerosis in Australia
- phase1Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
- phase2A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- EP1Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
- phase4Lipid Management in Renal Transplant Recipients Using Evolocumab.
- phase1Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
- phase4Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
News(10)
- STAT+: Democrats begin asking: How far can we go on health care?Many in the party are pushing for Democratic lawmakers to go big on health care, but their dreams may crash into reality.stat · 8d ago
- STAT+: Why the latest heart drug failures should make us all more skeptical of AI hypeOnce again, a hot new technology that was supposed to speed up drug research has fallen flat.stat · 9d ago
- STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countriesThe model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.stat · 9d ago
- STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategyMedical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.stat · 9d ago
- STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories“These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease."stat · 9d ago
- STAT+: Democrats’ midterm landslide spells relief for hospitalsDemocrats are likely to focus on reversing Medicaid cuts and expanding insurance coverage, giving a boost to health care providers.stat · 10d ago
- STAT+: New tumor cases show common gene therapy tool can come with riskNew cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.stat · 10d ago
- Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack riskPlus, news about MetaVia, Agios Pharmaceuticals and Inovio. Satellos Bioscience changes Duchenne study primary endpoint: The company is studying a small-molecule drug called forazapadin aimed at he…endpoints · 10d ago
- STAT+: Amgen’s Repatha linked to fewer heart attacksPithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma,…stat · 10d ago
- STAT+: Beyond statins, one drug lowered heart attack risk by 20%A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."stat · 11d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that